Sartorius Supervisory Board Appoints Two New Executive Board Members
At today’s meeting, the Supervisory Board of Sartorius AG resolved to make changes in the Executive Board. Effective January 1, 2019, Dr. René Fáber as Head of the Bioprocess Solutions Division and Gerry Mackay as Head of the Lab Products & Services Division will be appointed new members of the company’s Executive Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181206005621/en/
René Fáber (Photo: Business Wire)
René Fáber, age 43, has been working at Sartorius since 2002. He started as an R&D Scientist in the Membrane Modification Department, then headed R&D Process Technologies. Later, as Vice President, he held various management positions in Marketing for Filtration and Fermentation Technologies, as well as in Key Account Management. In his most recent position before his appointment to the Executive Board, he was responsible for the entire Product Development unit of the Bioprocess Solutions Division. René Fáber studied chemistry in Bratislava, Slovakia, and earned his Ph.D. in polymer chemistry at the Technical University of Munich in Germany. He is of Slovakian nationality.
Gerry Mackay, age 56, joined Sartorius in 2015 from the acquisition of BioOutsource, where he had been its CEO since 2009. Prior to his tenure with BioOutsource, he held international senior level positions in Sales and Marketing at several companies, among them at the U.S. life science company Millipore. At Sartorius, Gerry Mackay as Head of Marketing, Sales and Services of the Lab Products & Services Division drove the momentum of the division‘s new strategic direction towards the biopharmaceutical market and its respective applications and technologies. Gerry Mackay holds a Bachelor’s of Science Honors degree in biochemistry and a Master’s in education, and is of British nationality.
Furthermore, the Supervisory Board and Executive Board member Reinhard Vogt mutually and amicably agreed on the best of terms that the latter will step down from his position on the Executive Board as of December 31, 2018. The Supervisory Board thanks him for his extraordinarily successful service that he has dedicated to the benefit of the company for more than 35 years in various functions, the most recent of which as a member of the Executive Board since 2009. “Mr. Vogt has outstandingly served the company, especially in the strategic alignment and operational leadership of the Bioprocess Solutions Division, which today represents the largest pillar in sales revenue and earnings of the Sartorius Group. We wish Mr. Vogt all the best for the future, in which he will continue to support Sartorius, among other companies, in an advisory capacity,” said Dr. Lothar Kappich, Chairman of the Supervisory Board. “At the same time, we are also pleased to welcome René Fáber and Gerry Mackay, two internationally experienced and successful managers from our own ranks, to join our Executive Board.“
As of January 1, 2019, the Sartorius Executive Board will thus consist of the four following members: Dr. Joachim Kreuzburg (Chairman and CEO); Dr. René Fáber (Head of Bioprocess Solutions), Gerry Mackay (Head of Lab Products & Services); and Rainer Lehmann (Chief Financial Officer).
A profile of Sartorius
The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2017, Sartorius earned sales revenue of more than 1.4 billion euros. Currently, more than 8,000 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Defence Unlimited International Corp. is Hiring Veterans17.7.2019 20:58:00 CEST | Press release
Defence Unlimited International is one of the fastest growing companies operating within the defence and security space. Defence Unlimited International has adopted a unique outsourced model which integrates multiple partners both individual and corporate, on its projects. This has enabled it to offer and deliver to its clients best of breed bespoke solutions. Whilst Defence Unlimited is pursuing its drive towards achieving a more global footprint in its operations, the founder, Edward Banayoti firmly reiterates the continued commitment of the company to its existing strategy of identifying and successfully deploying experienced individuals that have served in the military. Individuals and teams with such experience can offer invaluable value added within projects Defence Unlimited are active in or are in the process of executing. "We take pride in our track record of offering numerous opportunities to Veterans who have served their country, giving such individuals who have heeded a pa
Temenos Acquires a SaaS-based, Patented, Explainable AI (XAI) Platform to Accelerate its AI Roadmap and Expertise17.7.2019 16:22:00 CEST | Press release
Contact information Media Contacts Jessica Wolfe Temenos Global Public Relations Tel: +1 610 232 2793 Email : firstname.lastname@example.org Alistair Kellie & Andrew Adie Newgate Communications on behalf of Temenos Tel: +44 20 7680 6550 Email: email@example.com
Gartner Names Airship a Leader, Positioned Highest in Execution and Furthest in Vision in the Magic Quadrant for Mobile Marketing Platforms17.7.2019 15:59:00 CEST | Press release
Customer engagement company Airship today announced that it has been named a Leader by Gartner, Inc. in its 2019 Magic Quadrant for Mobile Marketing Platforms1. Among 18 vendors evaluated, Airship was positioned highest in its ability to execute and also furthest for its completeness of vision. A complimentary copy of the full report is available from Airship. “We believe Gartner’s positioning of Airship validates our unique ability to deliver innovative, transformative digital customer experiences for the world’s leading brands,” said Brett Caine, CEO and president, Airship. “Airship delivers rich messages with pinpoint accuracy on whatever channel is most convenient and effective for the customer. Today’s customer expects proactive information and real-time response, and Airship is the essential component that makes it all possible.” According to Gartner, “Globally, consumers spend more of their time on smartphones than on desktops, laptops or tablets. This broad and rapid consumer a
GSMA Signs £38 Million Funding Partnership With the Department of International Development17.7.2019 15:02:00 CEST | Press release
The GSMA today announced that it has signed a thirty-eight million-pound partnership with the UK’s Department for International Development (DFID). The ‘Partnership for Inclusion, Innovation and Scale’ will provide funding for the GSMA’s Mobile for Development work on digital inclusion, digital identity, energy, water, sanitation and the reduction of the mobile gender gap. It will also include two new areas of focus: disability and climate. “This landmark partnership with DFID reinforces the joint power and potential of the private and public sectors working together and ensures that we will continue our crucial role of stimulating digital innovation to deliver both sustainable business and large-scale socio-economic impact for the underserved,” said Mats Granryd, Director General, GSMA. “This project reinforces our commitment to supporting the UN’s Sustainable Development Goals and using the power of technology to reduce global inequalities.” Inclusion, Innovation and Scale The partne
Gilead Sciences Announces Changes to Senior Leadership Team17.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) announced today changes to the company’s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead. Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function. Mr. Alton joined Gilead in 1999 and most recently has led Gilead’s corporate and medical affairs functions and developing world access programs, as well as commercial operations in certain countries of Asia and Latin America. He previously served as general counsel and helped to architect the company’s innovative access model for HIV and viral hepatitis medicines in resource-limited countries. He will remain with Gilead through October 4 and plans to serve in an advisory capacity until the end of the year to help transition his responsibilities to other parts of the organization. “Gregg has been a valued leader at Gilead for nearly 20
Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company17.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. The company will immediately commence a search for his successor. Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company’s expansion into oncology with the development of Gilead’s first cancer medicine, Zydelig® (idelalisib). He was appointed Chief Scientific Officer in March 2018. During his tenure, he has been responsible for broadening and overseeing the company’s Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation. “Over the past nine years, John’s scientific contributions and le